Skip to main content

Advertisement

Fig. 2 | Chinese Journal of Cancer

Fig. 2

From: Association of post-treatment hypoalbuminemia and survival in Chinese patients with metastatic renal cell carcinoma

Fig. 2

Overall survival (OS) and progression-free survival (PFS) curves of patients with metastatic renal cell carcinoma with and without post-treatment hypoalbuminemia who received sorafenib or sunitinib as first-line therapy. In the post-treatment hypoalbuminemia group, OS (a) and PFS (b) rates are significantly lower than those in the normal post-treatment albumin level group

Back to article page